Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes

被引：0
|
作者：
Kovacs, C. S. [1 ]
Seshiah, V. [2 ]
Merker, L. [3 ]
Christiansen, A. Vedel [4 ]
Roux, F. [5 ]
Salsali, A. [6 ]
Kim, G. [6 ]
Stella, P. [6 ]
Woerle, H. J. [6 ]
Broedl, U. C. [6 ]
机构：
[1] Mem Univ Newfoundland, Hlth Sci Ctr, St John, NF A1C 5S7, Canada
[2] Diabet Care & Res Inst, Chennai, Tamil Nadu, India
[3] Diabet & Nierenzentrum, Dormagen, Germany
[4] Boehringer Ingelheim Danmark AS, Copenhagen, Denmark
[5] Boehringer Ingelheim France, Reims, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [41] Long-term (2-year) effects on serum lipids of pioglitazone, gliclazide and metformin as add-on therapies in patients with Type 2 diabetes
    Mariz, S
    Tan, MH
    Moules, I
    Edwards, G
    Urquhart, R
    DIABETOLOGIA, 2004, 47 : A261 - A262
  • [42] Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
    Masato Odawara
    Izumi Hamada
    Manabu Suzuki
    Diabetes Therapy, 2014, 5 : 169 - 181
  • [43] Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
    Odawara, Masato
    Hamada, Izumi
    Suzuki, Manabu
    DIABETES THERAPY, 2014, 5 (01) : 169 - 181
  • [44] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    DIABETES, 2016, 65 : A293 - A293
  • [45] Effect of Add-On Therapy of Dapagliflozin and Empagliflozin on Adipokines in Type 2 Diabetes Mellitus
    Shaheer, Abid
    Kumar, Ashok
    Menon, Palat
    Jallo, Mahir
    Basha, Shaikh
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2021, 11 (3-4) : 83 - 90
  • [46] Tirzepatide as an Add-on for Patients with Type 2 Diabetes
    不详
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (12) : 737 - 738
  • [47] Better adherence with vildagliptin add-on to metformin than sulphonylurea add-on to metformin among Muslim patients with type 2 diabetes mellitus fasting during Ramadan
    Hanif, W.
    Malik, W.
    Hassanein, M.
    Kamal, A.
    Geransar, P.
    Lister, N.
    Andrews, C.
    Barnett, A. H.
    DIABETOLOGIA, 2011, 54 : S342 - S342
  • [48] Trends in add-on medications following metformin monotherapy for type 2 diabetes
    Swart, Elizabeth C. S.
    Neilson, Lynn M.
    Munshi, Kiraat
    Peasah, Samuel K.
    Henderson, Rochelle
    Good, Chester B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (11): : 1253 - 1259
  • [49] Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
    Schubert, Agata
    Buchholt, Anders T.
    El Khoury, Antoine C.
    Kamal, Ahmed
    Taieb, Vanessa
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (06) : 1155 - 1163
  • [50] Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A279 - A279
12345